Ignite Creation Date:
2024-05-06 @ 12:34 PM
Last Modification Date:
2024-10-26 @ 1:01 PM
Study NCT ID:
NCT03797326
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-10-31
First Post:
2019-01-07
Brief Title:
Efficacy and Safety of Pembrolizumab MK-3475 Plus Lenvatinib E7080MK-7902 in Previously Treated Participants With Select Solid Tumors MK-7902-005E7080-G000-224LEAP-005
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Multicenter Open-label Phase 2 Study of Lenvatinib E7080MK-7902 Plus Pembrolizumab MK-3475 in Previously Treated Subjects With Selected Solid Tumors LEAP-005
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the safety and efficacy of combination therapy with pembrolizumab MK-3475 and lenvatinib E7080MK-7902 in participants with triple negative breast cancer TNBC ovarian cancer gastric cancer colorectal cancer CRC glioblastoma GBM biliary tract cancers BTC or pancreatic cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2018-003747-37 | EUDRACT_NUMBER | Merck | None |
| MK-7902-005 | OTHER | None | None |
| E7080-G000-224 | OTHER | None | None |
| LEAP-005 | OTHER | None | None |